HomeOpen Access NewsClinical Trials

Clinical Trials

Gene therapy can restore vision in patients with rare inherited condition

Researchers at the Perelman School of Medicine at the University of Pennsylvania have reported improvements in vision among patients with a rare inherited condition, following gene therapy.

New UK study will mix Moderna and Novavax COVID doses

Researchers in the UK started a clinical trial on mixing vaccines in February - today (14 April) a new study will look into mixing Moderna and Novavax doses.

US stops Johnson & Johnson vaccine to investigate blood clot risk

US authorities paused the use of the Johnson & Johnson single dose vaccine as they look into six cases of blood clots that developed in women aged between 18 and 48.

Clinical trial finds COVID antibody drug can prevent infection

Uninfected people lived with one infected individual as part of the study - the COVID antibody drug gave them 72% protection against catching the virus themselves.

Over 700,000 AstraZeneca doses sent from UK to Australia

Today (8 April) it was revealed that over 700,000 AstraZeneca doses manufactured in the UK are being sent to Australia - with a confirmed 300,000 vaccines in Sydney at the end of February.

Moderna COVID vaccine rollout begins in UK

The Moderna COVID vaccine will initially be given to patients in Wales - which brings the UK up to three approved vaccines.

Scientists find Pfizer vaccine is 100% effective in young adolescents

The company aim to start vaccinating children by September 2021, as clinical trials reveal that Pfizer is 100% effective in those aged 12 to 15.

Moderna and Pfizer vaccines 90% effective in US real-world data

Real-world use of the Moderna and Pfizer vaccines in the United States reveals that both are working at 90% efficacy - with data pointing to one dose being capable of 80% protection.

Biosimilars: Improve access to treatment & reduce cost

Tore K Kvien & Guro L Goll argue that biosimilars are an opportunity for improving access to treatment & reducing cost and provide comment on the NOR-SWITCH study.

AstraZeneca vaccines made for UK could be kept for EU use only

EU leaders today (25 March) decided not to create an export ban for AstraZeneca vaccines made for the UK - but the feud between AstraZeneca and the bloc remains close to the surface of future discussions.

US trial finds AstraZeneca vaccine 100% effective against COVID death

In a study of over 32,000 people, a US trial found the AstraZeneca vaccine was 100% effective against deaths caused by COVID-19 - the vaccine did not show any connection to blood clots.

Polymers and polymer-based drug delivery in the treatment of dry eye disease

Professor Heather Sheardown, C20/20 Ophthalmic Materials Innovation Hub, Department of Chemical Engineering, McMaster University, explores how polymers can be used to treat dry eye disease.

European Medicines Agency say AstraZeneca does not cause blood clots

The safety committee of the European Medicines Agency said the investigation did not prove that AstraZeneca vaccinations cause blood clots - describing the possibility as an "extremely small likelihood".

COVID-19: The evolution of testing & sequencing

Novacyt Group, discusses the evolution of testing and sequencing during COVID-19 with a panel of distinguished speakers.

Birth control creates higher risk of blood clots than AstraZeneca vaccine

Currently, several EU countries are suspending use of the AstraZeneca vaccine due to reports of blood clot risks - in response, people are speaking out about the higher risk of blood clots posed by contraceptive pills used globally.

European Medicines Agency says AstraZeneca vaccine still safe to use

Over the weekend, the Republic of Ireland suspended their use of AstraZeneca due to reports of blood clots in Norway - in response, the European Medicines Agency (EMA) says the AstraZeneca vaccine is still safe to use.

Novavax 96.4% effective against the original COVID mutation

The US based vaccine appears to be 96.4% effective against the original COVID mutation, with 86% efficacy against the UK variant and only 55% against the South African variant.

Advertisements


Latest Academic Articles

The latest academic articles from key research stakeholders